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Background: This study evaluated the relationship between the G(-866)A polymorphism of the uncoupling protein
2 (UCP2) gene and high-sensitivity C reactive protein (hs-CRP) plasma levels in diabetic patients.
Methods: We studied 383 unrelated people with type 2 diabetes aged 40-70 years. Anthropometry, fasting lipids,
glucose, HbA1c, and hs-CRP were measured. Participants were genotyped for the G (-866)A polymorphism of the
uncoupling protein 2 gene.
Results: Hs-CRP (mg/L) increased progressively across the three genotype groups AA, AG, or GG, being respectively
3.0 ± 3.2, 3.6 ± 5.0, and 4.8 ± 5.3 (p for trend = 0.03). Since hs-CRP values were not significantly different between
AA and AG genotype, these two groups were pooled for further analyses. Compared to participants with the AA/
AG genotypes, homozygotes for the G allele (GG genotype) had significantly higher hs-CRP levels (4.8 ± 5.3 vs 3.5
± 4.7 mg/L, p = 0.01) and a larger proportion (53.9% vs 46.1%, p = 0.013) of elevated hs-CRP (>2 mg/L). This was
not explained by major confounders such as age, gender, BMI, waist circumference, HbA1c, smoking, or
medications use which were comparable in the two genotype groups.
Conclusions: The study shows for the first time, in type 2 diabetic patients, a significant association of hs-CRP
levels with the G(-866)A polymorphism of UCP2 beyond the effect of major confounders.
Background
Inflammation plays a key role in the pathogenesis of
atherosclerosis at every stage, from initiation to progres-
sion and rupture of the atherosclerotic plaque [1]. C
Reactive Protein (CRP), an acute phase protein synthe-
sized primarily by the liver, is the most widely used bio-
marker of inflammation and is also a powerful risk
marker for cardiovascular diseases [2]. Although obesity,
particularly of the visceral type, is a key determinant of
hs-CRP levels [3,4], twin and family studies indicate that
35-50% of the phenotypic variation of hs-CRP is geneti-
cally determined [5,6]. Uncoupling protein 2 (UCP2)
uncouples the substrate oxidation from ATP synthesis,
thus decreasing ATP production by the mitochondrial
respiratory chain. UCP2 is expressed in spleen, lung,
macrophages, and T cells, which suggests a role for
UCP2 in the regulation of immunity and inflammatory
responsiveness [7]. Furthermore, UCP2 functions as a
down-regulator of reactive oxygen species (ROS) whose
increased production induces vascular endothelial
damage, thus initiating the atherosclerotic process [8,9].
The UCP2 G(-866)A polymorphism is a functional poly-
morphism located in the promoter region of the gene.
In most, although not all studies, the G allele is asso-
ciated with lower mRNA expression levels [10-14], sug-
gesting a reduced protection against ROS production. In
line with this hypothesis, in UCP2 deficient mice the
ROS production in macrophages is 80% higher than in
wild type mice [15]. In addition, the -866 G allele is
associated with an increased risk of chronic inflamma-
tory diseases [16], and greater susceptibility to autoim-
mune diseases [10] and cardiovascular diseases [17-19].
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between the G(-866)A polymorphism of UCP2 and hs-
CRP plasma levels in type 2 diabetic patients. The role
of major confounders was also studied. This association
has never been explored, although potentially relevant
since it may contribute to the understanding of the pos-
sible mechanisms linking this polymorphism to cardio-
vascular risk.
Methods
Population: The study population was recruited at two
centres in two Italian cities (Naples and Turin), within
the framework of a project aimed at studying the emer-
ging risk factors for the chronic complications of dia-
betes, partially funded by the Italian Ministry of
University, Research and Technology (MURST prot.
2004-062128-001). Study participants were 383 (189
men and 194 women) unrelated patients with type 2
diabetes mellitus consecutively seen at the outpatient
clinics and recruited according to the following criteria:
type 2 diabetes diagnosed according to WHO, and aged
40 to 70 years. Exclusion criteria were overt renal or
hepatic diseases (serum creatinine > 2 mg/dl, ALT >
three times the normal values), autoimmune disorders,
chronic use of steroids or non steroidal anti-inflamma-
tory drugs, statin therapy, acute or chronic infections
(assessed by history, use of drugs, clinical examination,
and white cell count > 10.000/μL). The study was
approved by the local ethics committee and was con-
ducted in accordance to the Helsinki Declaration. All
participants signed an informed consent. The study was
conducted according to a standard protocol by ad-hoc
trained investigators who were unaware of the partici-
pant’s genotype status. All investigations took place in
the morning.
Measurements
Weight, height, and waist circumference were measured
with patients in light clothing and without shoes. BMI
was calculated. Waist circumference was measured at
the level of the umbilicus. Medication use was assessed
by interview and validated against clinical charts on a
random sample. Fasting glucose, triglycerides, total and
HDL cholesterol were measured by standard laboratory
methods on fresh plasma. Glycated hemoglobin was
measured by HPLC. Laboratory measurements were
standardized in the two centres. For all participants,
CRP was measured in Torino by a high sensitivity
method (Tina-Quant, Roche/Hitachi 904) on frozen
samples of EDTA-treated plasma.
Genotyping
Genotype analyses were centralized in Naples. Geno-
mic DNA was isolated from whole blood using
Biorobot EZ1 Qiagen. All the patients were genotyped
for the G(-866)A (rs659399) variation in the promoter
region of Uncoupling Protein 2 (UCP2) by polymerase
chain reaction (PCR). Oligoprimers were tested by gra-
dient PCR to optimize melting temperature. Genotyp-
ing was performed by an allele-specific amplification
method using SYBR Green detection in a Realtime ABI
PRISM 7000 apparatus (PE Applied Biosystem). To
ensure genotyping accuracy, the laboratory received 5%
of the samples in blind duplicates and results were
fully concordant. The G(-866)A genotype distribution
was in Hardy-Weinberg equilibrium and similar in the
two centres.
Statistical analysis
Data is given as means and standard deviations or per-
centages. Skewed variables (i.e. plasma triglycerides,
insulin and hs-CRP) were log transformed for the ana-
lyses and back transformed to the original values in
tables and figures. The X
2 goodness-of-fit test was used
to assess deviation from Hardy-Weinberg equilibrium of
the genotypic frequency by calculating expected fre-
quencies of genotypes. Group means were compared by
unpaired Student’s t-test or analysis of variance, as
appropriate. Proportions were compared by X
2 square
analysis. Multivariate analysis was conducted by linear
regression with hs-CRP as the outcome variable, the
independent variables included in the model were G
(-866)A polymorphism of UCP2, gender, age, glycated
hemoglobin, waist circumference, centre (Napoli - Tor-
ino). A p-value of less than 0.05 (two tailed) was consid-
ered significant. All statistical analyses were conducted
using Statistical Package for Social Science (SPSS) for
Windows version 14.0
Results
The study participants were middle aged (58.1 ± 7.9
years) and generally overweight (BMI 30.7 ± 5.9 kg/m
2).
Glucose control, as assessed by HbA1c, was on average
not optimal (HbA1c 7.4 ± 1.7%). The UCP2 genotype
distribution was in Hardy Weinberg equilibrium and
similar to that observed in other Caucasian populations:
i.e. 10.2% of the participants were AA, 41.5% were AG
and 48.3% were GG.
Hs-CRP plasma concentrations are shown in figure 1
by UCP2 genotype. Values progressively increased across
the three genotype groups, being lowest for carriers of
the AA genotype, intermediate for those with the AG
genotype and highest for the GG genotype, (respectively
3.0 ± 3.2 vs 3.6 ± 5.0 vs 4.8 ± 5.3 mg/L; p = 0.03, for
linear trend), thus suggesting a gene dose effect. The
ANOVA analysis of variance with post hoc tests showed
a statistically significant difference in hs-CRP values
between the GG genotype participants and those with
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1). Due to the small number of people with the AA gen-
otype, this group was pooled together with the AG gen-
otype in subsequent analyses.
Hs-CRP levels were 4.8 ± 5.3 vs 3.5 ± 4.7 mg/l in car-
riers of the GG genotype compared to those with the
AA/AG genotype (p = 0.01); accordingly, the proportion
of people with hsCRP > 2 mg/L - a value associated
with increased cardiovascular risk [20] - was signifi-
cantly higher in the group with the GG genotype (53.9%
vs 46.1%; p = 0.013) (table 1). No significant difference
between the two groups was observed for BMI and
waist circumference, two key determinants of CRP. Age,
gender, HbA1c, lipids and smoking status were also
comparable in the two genotype groups as it was the
proportion of patients treated with insulin, insulin secre-
tagogues, or insulin sensitizers (table 1).
Multivariate regression analysis (Table 2) confirmed a
significant association of the G(-866)A polymorphism of
UCP2 with hs-CRP independent of gender, age, waist
circumference, glucose control and centre. The finding
remained very much the same when a different model
was used, with BMI instead of waist circumference as a
covariate. A significant association of CRP with gender
and waist circumference was also observed.
Discussion
The results of this study show that in people with type 2
diabetes the G allele of the UCP2 G(-866)A polymorph-
ism is associated with elevated hs-CRP levels with a
gene dose effect, thus suggesting a markedly higher
inflammatory status in carriers of the GG genotype
compared to carriers of the AA/AG genotype. The find-
ing holds after correction for confounders such as waist
circumference, BMI and blood glucose control. In addi-
tion, people with acute or chronic inflammatory condi-
tions were excluded from the study thus ruling out
further confounders. The precise function of UCP2 is
still unknown. However, based on available evidence,
the UCP2 gene is a plausible biological candidate for a
role in the regulation of the inflammatory response. The
gene is expressed in a variety of cells including spleen
cells, macrophages and T cells. Moreover, the UCP2
protein functions as a down-regulator of reactive oxygen
species (ROS) generation [15]. Several studies have
shown that the UCP2 G(-866)A is a functional poly-
morphism with the G allele associated with lower
mRNA expression levels [10-14]. This is compatible
with a reduced protection against ROS production [21].
ROS modulate multiple signal transduction pathways -
activation of matrix metalloproteinase, vascular smooth
Figure 1 CRP plasma concentrations according to UCP2
genotype (p = 0.03 for trend).
Table 1 Characteristics of the study participants by UCP2 genotype
UCP 2 G(-866)A polymorphism AA+AG (N 198) GG (N 185) p
Age (years) 58.2 ± 7.5 58.0 ± 8.2 0.78
Males (%) 52.5 47.5 0.22
BMI (kg/m
2) 30.5 ± 5.9 30.9 ± 5.8 0.46
Waist circumference (cm) 100.9 ± 11.9 101.2 ± 12.0 0.82
Total cholesterol (mg/dl) 197.9 ± 37.9 205.2 ± 43.9 0.09
HDL cholesterol (mg/dl) 48.4 ± 11.7 48.6 ± 12.4 0.93
Triglycerides (mg/dl) 149.8 ± 100.8 146.8 ± 91.8 0.75
HBA1c (%) 7.4 ± 1.7 7.4 ± 1.7 0.78
Hs-CRP (mg/l) 3.5 ± 4.7 4.8 ± 5.3 0.01
Proportion (%) with hs-CRP > 2 mg/L 46.1 53.9 0.01
Current smokers (%) 47.0 36.8 0.10
Metformin (%) 25.6 29.7 0.48
Insulin secretagogues 19.8 25.0 0.61
Insulin (%) 54.5 45.3 0.34
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tion and lipid peroxidation - all of which are implicated
in the process of atherogenesis [22]. In addition, ROS
can activate the transcription factor NF-kB, that is ubi-
quitously expressed and mediates the expression of
genes involved in the acute inflammatory response,
including the cytokines IL1-IL6 and IL8 [23], which in
turn modulate CRP production. Therefore, it is plausible
to hypothesize that functional UCP2 gene polymorph-
isms leading to reduced expression of UCP2 may be
related to a proinflammatory status and possibly to the
development and progression of atherosclerosis. This
hypothesis is supported by studies in animals and in cell
culture [24,25]. Transplantation of UCP2 deficient bone
marrow cells to low density lipoprotein receptor defi-
cient mice markedly accelerated the formation of ather-
osclerotic lesions. Moreover, arterial walls isolated from
these mice had increased macrophage accumulation in
the atherosclerotic lesions [24].
In humans the common G allele was associated with
lower mRNA expression levels in several studies [10-14].
The G allele has also been associated with an increased
risk of chronic inflammatory diseases [10,16] and cardio-
vascular diseases [17]. Our study expands current knowl-
edge by providing the evidence that the GG genotype of
UCP2 is associated with increased circulating hs-CRP
levels beyond the effect of major confounders. To our
knowledge, while there is no previous data reporting a
relationship between the G(-866)A polymorphism of
U C P2a n dh s - C R Pw h i c hh a m p e r sc o m p a r i s o n ,t h e
results of the present study are in line with two recent
observational studies. One, conducted in healthy children
and adolescents, showed that the G variant of UCP2 was
associated with markers of low grade inflammation (i.e.
fibrinogen, complement C3 and complement C4) [26].
The other [17] demonstrated in two large independent
cohorts of diabetic subjects that the G allele was asso-
ciated with increased risk of coronary artery disease com-
pared to the A allele, independent of major CV risk
factors; unfortunately CRP was not measured. However,
the association between the G(-866)A polymorphism of
the UCP2 and cardiovascular diseases is still debated, as
it is often the case with genetic association studies, since
some studies showed a protective effect of the A allele
against cardiovascular diseases [18,19], which is some-
what at variance with our results.
The role of genes in the etiology of cardiovascular dis-
eases and diabetes needs to be further explored. These
conditions are rapidly increasing worldwide largely due to
rapid changes in lifestyle related factor. However, the
genetic background plays a role in determining individual
susceptibility in response to similar environmental condi-
tions [27-29] and may provide a basis for identifying at risk
individuals at a young age thus allowing early prevention.
Among the study limitations we must acknowledge
that, due to the cross-sectional design, we cannot deter-
mine whether the UCP2 polymorphism is causally asso-
ciated with hs-CPR or the association is mediated
through other atherosclerosis-associated conditions. A
further limitation is the fact that hs-CRP levels were
measured only once in this study. However it has been
shown that the intraindividual variation of hs-CRP is
low and that this parameter is reasonably stable when
compared at various points in time, several years apart
[30]. In addition, we carefully excluded people with
acute or chronic inflammatory conditions thus further
reducing variability.
Conclusion
This study provides the evidence of an association
between UCP2 G(-866)A polymorphism and hs-CRP
levels in type 2 diabetic patients. The finding may con-
tribute to the understanding of the role of this poly-
morphism in the modulation of cardiovascular risk by
providing evidence for a biologically plausible mechan-
ism. This being the first report, the findings need to be
replicated in other populations with or without diabetes.
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